At ASCO, the CHRYSALIS-2 study read-out showed that patients on the combination had overall survival of nearly three-and-a-half years.

For more than four decades, oncologists have known that a single protein drives nearly all pancreatic cancers, and for just as long, they have had no way to shut it off. The protein, KRAS, mutates in ...

Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, ...

(UroToday.com) The 2026 American Society of Clinical Oncology Genitourinary (ASCO) Annual Meeting, held in Chicago, IL, will host the Prostate, Testicular, and Penile Cancer – Posters Session. Dr.

The UK's National Screening Committee has concluded its review of prostate cancer screening in the UK, saying that the harms of a large-scale, national programme would outweigh the benefits. The ...

When Garen was diagnosed with lung cancer, biomarker testing helped focus his treatment options, inform his treatment decisions, and finding the appropriate treatment has allowed him to maintain his ...

Britain’s refusal to introduce meaningful prostate cancer screening is rapidly becoming one of the great scandals of modern healthcare. Every hour, a man dies from prostate cancer in this country. Yet ...

As few as 3,000 men will be invited for screening, which will involve taking a blood test every two years to check for a ...

A genetic mutation carried by Homo erectus, a human ancestor who disappeared roughly 250,000 years ago, has been found in ...

Only "a few thousand" men who have a dangerous genetic variant and a family history of cancer should be screened, experts say ...

The National Screening Committee said attempting to detect the disease using the specific antigen blood test was 'likely to ...

Some patients have a mutation that causes them to not produce CA19-9, a tumor marker often used to help determine prognosis.